艰难梭菌感染的诊断、发病机制与治疗更新
艰难梭菌感染是医疗相关感染性腹泻的首位病因,对内科和外科患者均构成显著风险。本文综述其流行病学、临床表现谱及诊疗策略,强调早期手术会诊,并根据指南推荐全腹结肠切除加回肠末端造口,或作为替代的转流性袢式回肠造口加结肠灌洗。
要点
- 艰难梭菌感染是医疗相关感染性腹泻的首位病因,外科、结肠切除术后及炎症性肠病患者为高危人群。
- 临床表现从轻度腹泻到暴发性结肠炎、小肠肠炎及复发性感染,需保持高度警惕。
- 指南推荐早期手术会诊;可选全腹结肠切除加回肠末端造口,或选择性患者行转流性袢式回肠造口加结肠灌洗。
核心结论
- 艰难梭菌感染是医疗相关感染性腹泻的首位病因,对内科和外科患者均构成显著风险。
- 早期实施药物和手术治疗策略对获得最佳患者结局至关重要。
- 外科医生是艰难梭菌感染预防和治疗临床团队的重要组成部分。
研究设计与样本
- 本文为综述,总结艰难梭菌感染的诊断、发病机制和治疗更新。
主要发现
- 艰难梭菌感染表现为从轻度腹泻到暴发性结肠炎或小肠肠炎及复发性感染的广泛疾病谱。
- 国家和国际指南推荐早期手术会诊以及全腹结肠切除加回肠末端造口并保留直肠。
- 在选择性患者中,可考虑转流性袢式回肠造口加结肠灌洗,随后经回肠造口输出袢给予静脉甲硝唑和结肠内万古霉素,作为全结肠切除术的替代方案。
- 新出现的治疗策略包括单克隆抗体、疫苗、益生菌、生物治疗剂和新型抗生素。
关键数值与推荐
- 指南推荐早期手术会诊和全腹结肠切除加回肠末端造口并保留直肠。
- 选择性患者可考虑转流性袢式回肠造口加结肠灌洗,随后经回肠造口输出袢给予静脉甲硝唑和结肠内万古霉素,作为全结肠切除术的替代方案。
临床怎么用
- 对艰难梭菌感染患者应保持高度警惕,尤其外科、结肠切除术后和炎症性肠病患者。
- 早期实施药物和手术治疗策略,并早期请外科会诊。
- 根据指南选择全腹结肠切除加回肠末端造口,或在选择性患者中采用转流性袢式回肠造口加结肠灌洗。
- 成功的预防和根除计划需要多学科方法,包括早期识别、环境控制监测、手卫生、循证治疗和抗生素管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clostridium difficile infections are the leading cause of health care-associated infectious diarrhea, posing a significant risk for both medical and surgical patients. Because of the significant morbidity and mortality associated with C difficile infections, knowledge of the epidemiology of C difficile in combination with a high index of suspicion and susceptible patient populations (including surgical, postcolectomy, and inflammatory bowel disease patients) is warranted. C difficile infections present with a wide spectrum of disease, ranging from mild diarrhea to fulminant colitis or small bowel enteritis and recurrent C difficile infections. Early implementation of medical and operative treatment strategies for C difficile infections is imperative for optimal patient outcomes. National and international guidelines recommend early operative consultation and total abdominal colectomy with end ileostomy and preservation of rectum. Diverting loop ileostomy and colonic lavage followed by intravenous metronidazole and intracolonic vancomycin administered via the efferent limb of the ileostomy should be considered as an alternative to total colectomy in selected patients. New and emerging strategies for C difficile infection treatment include monoclonal antibodies, vaccines, probiotics, biotherapeutics, and new antibiotics. A successful C difficile prevention and eradication program requires a multidisciplinary approach that includes early disease recognition, implementation of guidelines for monitoring adherence to environmental control, judicious hand hygiene, evidence-based treatment and management strategies, and a focused antibiotic stewardship program. Surgeons are an important part of the clinical team in the management of C difficile infection prevention and treatment.
引用
- Napolitano LM, Edmiston CE. Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. Surgery. 2017. PMID: 28267992. doi:10.1016/j.surg.2017.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。